Psoriasis is a chronic, inflammatory disease that affects about 10 million individuals in the United States. New psoriasis treatments target the dysregulated immune system functions responsible for disease pathogenesis. However, many of these immune pathways are also responsible for protecting the body from fungal and bacterial infections. Due to the increasing number of biologic therapies recently approved to treat psoriasis, understanding the comparative infectious risk associated with different biologic therapies is of upmost importance.